GeoVax Announces Reverse Stock Split

1:2000 Reverse Split Effective January 24, 2020;

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Thursday, January 23, 2020

Information

Tags:

Vaccines, Viruses, Medical specialties, GeoVax, Vaccine, HIV vaccine, Medicine

Geotags:

, ,

Organisation:

GEOVAX, INC.

Summary

Key Points:

1:2000 Reverse Split Effective January 24, 2020;
ATLANTA, GA, Jan. 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE GeoVax Labs, Inc. (OTC: GOVX) today announced it has implemented a 1-for-2000 reverse stock split of its common stock with a market effective date of January 24, 2020.
For the 20-business day period beginning January 24, 2020, GeoVaxs ticker symbol will be "GOVXD" to reflect the post-split price.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented MVA-VLP based vaccine platform.
GeoVaxs HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV.

1:2000 Reverse Split Effective January 24, 2020;
Ticker Symbol Changed to GOVXD for 20 Days

ATLANTA, GA, Jan. 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTC: GOVX) today announced it has implemented a 1-for-2000 reverse stock split of its common stock with a market effective date of January 24, 2020. For the 20-business day period beginning January 24, 2020, GeoVax’s ticker symbol will be "GOVXD" to reflect the post-split price. Following that period, the ticker symbol will revert to "GOVX."

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented MVA-VLP based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

GeoVax’s current development programs are focused on preventive vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections and multiple cancers. The Company has designed the leading preventative HIV vaccine candidate to fight against the subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan, and Australia; this program is currently undergoing human clinical trials managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV. For more information, visit www.geovax.com.

Contact: 
GeoVax Labs, Inc.
[email protected]
678-384-7220